LOS ANGELES CAPITAL MANAGEMENT LLC

Position in PRTA — Prothena Corp Public Ltd Co

CIK 1177206 LOS ANGELES, CA

Position in PRTA

as of Jun 30, 2026 · filed Aug 13, 2026 Compact

Position Value

$3,299

-$234,053 QoQ

Shares Held

337

-98.6% QoQ

Ownership

0.001%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#149

of 187 holders

Holding Since

Mar 2020

14 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

LOS ANGELES CAPITAL MANAGEMENT LLC holds $888,562,834 across 167 Biotechnology names. PRTA ranks #158 (0.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ALNY	Alnylam Pharmaceuticals, Inc.	729,635	$219,642,024
2	HALO	Halozyme Therapeutics, Inc.	1,938,035	$151,689,999
3	CAI	Caris Life Sciences, Inc.	3,958,531	$70,541,022
4	INCY	Incyte Corp	578,986	$65,633,852
5	VRTX	Vertex Pharmaceuticals Inc / Ma	130,802	$64,973,277
6	EXEL	Exelixis, Inc.	1,159,457	$63,086,055
7	REGN	Regeneron Pharmaceuticals, Inc.	98,585	$61,471,690
8	RPRX	Royalty Pharma plc	877,674	$49,211,181

14 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$3,299	337	-98.6%	Shares	Sole	2026-08-13
2026-03-31	$237,352	24,419	-74.4%	Shares	Sole	2026-05-08
2025-12-31	$911,127	95,406	-20.1%	Shares	Sole	2026-02-11
2025-09-30	$1,165,578	119,424	+615.0%	Shares	Sole	2025-10-20
2025-06-30	$101,381	16,702	+199.5%	Shares	Sole	2025-08-07
2022-12-31	$335,954	5,576	-8.7%	Shares	Sole	2023-02-06
2022-09-30	$370,206	6,106	-65.4%	Shares	Sole	2022-11-02
2021-09-30	$1,256,853	17,645	-48.8%	Shares	Sole	2021-11-08
2021-06-30	$1,773,387	34,495	-11.9%	Shares	Sole	2021-08-05
2021-03-31	$984,076	39,175	-1.0%	Shares	Sole	2021-05-05
2020-12-31	$475,295	39,575	-5.0%	Shares	Sole	2021-03-10
2020-09-30	$416,033	41,645	+2.1%	Shares	Sole	2020-11-02
2020-06-30	$426,611	40,785	+107.0%	Shares	Sole	2020-08-05
2020-03-31	$210,790	19,700	—	Shares	Sole	2020-05-04
No filing history on record for this holder in this stock.